L&S Knock-Out AYJ/ DE000LX3ZH86 /
05/07/2024 21:50:12 | Chg.-0.040 | Bid22:00:44 | Ask22:00:44 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.550EUR | -6.78% | - Bid Size: - |
- Ask Size: - |
VALNEVA SE EO... | 2.8595 EUR | 31/12/2078 | Call |
GlobeNewswire
01/07
Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ...
GlobeNewswire
26/06
Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Direct...
GlobeNewswire
24/06
Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ®
GlobeNewswire
05/06
Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Co...
GlobeNewswire
03/06
Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases
GlobeNewswire
13/05
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya...
GlobeNewswire
07/05
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire
25/03
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
GlobeNewswire
21/03
Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th Wo...
GlobeNewswire
20/03
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
GlobeNewswire
18/03
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and Orbi...
GlobeNewswire
04/03
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
GlobeNewswire
29/02
U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHI...
GlobeNewswire
10/01
Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine
GlobeNewswire
04/01
Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Foru...
GlobeNewswire
04/12/2023
Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, ...